Pharmacodynamics of Omiganan BID in Patients With Atopic Dermatitis
Status:
Completed
Trial end date:
2017-12-20
Target enrollment:
Participant gender:
Summary
This study has a randomized, double-blind, placebo-controlled design to assess the efficacy,
pharmacodynamics and safety/tolerability of omiganan in patients with mild to moderate atopic
dermatitis when applied BID to all atopic dermatitis lesions.